ADMA Biologics (NASDAQ:ADMA) Stock Rating Upgraded by Zacks Research

ADMA Biologics (NASDAQ:ADMA - Get Free Report) was upgraded by Zacks Research from a "strong sell" rating to a "hold" rating in a research report issued on Wednesday, Zacks reports.

• 3 Biotech Firms With Major Potential Catalysts in the Coming Months

A number of other equities research analysts have also issued reports on ADMA. Mizuho reduced their price target on ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating on the stock in a research report on Wednesday, July 15th. Canaccord Genuity Group dropped their price objective on shares of ADMA Biologics from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, May 7th. Weiss Ratings reissued a "hold (c)" rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Finally, Raymond James Financial assumed coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They issued an "outperform" rating and a $21.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $18.67.

Check Out Our Latest Stock Analysis on ADMA

ADMA Biologics Stock Up 0.7%

• 3 Mid-Cap Medical Stocks Outperforming the Market

ADMA Biologics stock opened at $9.58 on Wednesday. ADMA Biologics has a twelve month low of $7.21 and a twelve month high of $20.46. The stock's fifty day simple moving average is $9.13 and its 200-day simple moving average is $10.31. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $2.15 billion, a P/E ratio of 13.69 and a beta of 0.78.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.16. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The firm had revenue of $124.39 million during the quarter, compared to analyst estimates of $125.34 million. During the same period last year, the business posted $0.14 earnings per share. ADMA Biologics's revenue was up 2.0% compared to the same quarter last year. As a group, equities analysts expect that ADMA Biologics will post 0.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ADMA Biologics

• There May Still Be Time to Get in on These 3 Trending Biotechs

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in ADMA Biologics in the 2nd quarter valued at approximately $321,037,000. State Street Corp boosted its position in shares of ADMA Biologics by 0.3% in the fourth quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company's stock worth $248,014,000 after acquiring an additional 35,614 shares during the last quarter. Sachem Head Capital Management LP grew its holdings in ADMA Biologics by 27.0% in the fourth quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company's stock valued at $207,480,000 after purchasing an additional 2,415,000 shares during the period. Westfield Capital Management Co. LP increased its position in ADMA Biologics by 36.9% during the fourth quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company's stock worth $127,551,000 after purchasing an additional 1,886,105 shares during the last quarter. Finally, Capital Research Global Investors increased its position in ADMA Biologics by 104.0% during the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company's stock worth $121,067,000 after purchasing an additional 3,383,559 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

(Get Free Report)

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

Further Reading

• Five stocks we like better than ADMA Biologics
• The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
• NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
• Dropping the Dough: Yum! Brands Strategically Trims the Fat
• These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ADMA Biologics Right Now?

Before you consider ADMA Biologics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.

While ADMA Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here